MARKET

HNSBF

HNSBF

Hansa Medical AB
EXMKT
2.900
NaN%
Opening 09:30 05/20 EDT
OPEN
--
PREV CLOSE
2.900
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
3.300
52 WEEK LOW
2.900
MARKET CAP
295.11M
P/E (TTM)
-3.4957
1D
5D
1M
3M
1Y
5Y
1D
Hansa Biopharma: Buy Rating Reiterated as SERB Deal De-Risks Balance Sheet; SEK103 Price Target Maintained on U.S. Opportunity Upside
TipRanks · 18h ago
Hansa Biopharma Licenses IDEFIRIX to SERB in €115 Million Europe–MENA Deal
TipRanks · 1d ago
Hansa Biopharma CEO to Discuss Scaling Nordic Biotechs at LSX Nordic Congress
TipRanks · 2d ago
Hansa Biopharma to Highlight Immunotherapy Platform at H.C. Wainwright BioConnect Conference
TipRanks · 05/12 17:32
Hansa Biopharma Calls 2026 AGM With Governance and Incentive Plan on Agenda
TipRanks · 04/28 06:54
Hansa Biopharma Balances Setback and Progress on Earnings
TipRanks · 04/28 00:02
Buy Rating Maintained on Hansa Biopharma as Temporary Q1 Weakness Sets Stage for Rebound and Long-Term Growth
TipRanks · 04/24 10:25
Hansa Biopharma GAAP EPS of -SEK1.93, revenue of SEK34.57M
Seeking Alpha · 04/23 15:32
More
About HNSBF
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.

Webull offers Hansa Biopharma AB stock information, including EXMKT: HNSBF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HNSBF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HNSBF stock methods without spending real money on the virtual paper trading platform.